Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Zielinski C.
•
Gligorov J.
•
Marschner N.
altro
von Minckwitz G.
2016
Periodico
ANNALS OF ONCOLOGY
DOI
WOS
Archivio
Diritti
closed access